Dysmenorrhea

Human medicines European public assessment report (EPAR): Drovelis, estetrol,drospirenone, Date of authorisation: 19/05/2021, Revision: 5, Status: Authorised

Retrieved on: 
Tuesday, January 2, 2024

Human medicines European public assessment report (EPAR): Drovelis, estetrol,drospirenone, Date of authorisation: 19/05/2021, Revision: 5, Status: Authorised

Key Points: 


Human medicines European public assessment report (EPAR): Drovelis, estetrol,drospirenone, Date of authorisation: 19/05/2021, Revision: 5, Status: Authorised

Human medicines European public assessment report (EPAR): Lydisilka, estetrol,drospirenone, Date of authorisation: 19/05/2021, Revision: 4, Status: Authorised

Retrieved on: 
Tuesday, January 2, 2024

Human medicines European public assessment report (EPAR): Lydisilka, estetrol,drospirenone, Date of authorisation: 19/05/2021, Revision: 4, Status: Authorised

Key Points: 


Human medicines European public assessment report (EPAR): Lydisilka, estetrol,drospirenone, Date of authorisation: 19/05/2021, Revision: 4, Status: Authorised

Daré Bioscience Announces Positive Topline Pharmacokinetic and Exploratory Efficacy Results from the DARE-PDM1 Phase 1 Clinical Study

Retrieved on: 
Wednesday, December 20, 2023

SAN DIEGO, Dec. 20, 2023 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health innovation, today announced positive topline results from the Phase 1 study evaluating the pharmacokinetics (PK), safety, and exploratory efficacy of DARE-PDM1.

Key Points: 
  • SAN DIEGO, Dec. 20, 2023 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health innovation, today announced positive topline results from the Phase 1 study evaluating the pharmacokinetics (PK), safety, and exploratory efficacy of DARE-PDM1.
  • The DARE-PDM1 Phase 1 study, DARE-PDM1-001, was a multi-center, randomized, placebo-controlled, double-blind, 3-arm parallel group study among approximately 42 healthy, premenopausal women with symptomatic primary dysmenorrhea.
  • The vaginal fluid PK results exhibited dose proportionality for the 1% and 3% diclofenac strengths of the DARE-PDM1 study treatment.
  • Pending the plasma PK data, the topline results of this Phase 1 study support continued clinical development of DARE-PDM1 for primary dysmenorrhea.

Agios Presents Positive Results from Phase 2 Portion of the RISE UP Pivotal Study in Sickle Cell Disease at 65th ASH Annual Meeting and Exposition

Retrieved on: 
Sunday, December 10, 2023

CAMBRIDGE, Mass., Dec. 09, 2023 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a leader in the field of cellular metabolism pioneering therapies for rare diseases, today presented detailed results from the Phase 2 portion of the global RISE UP study of mitapivat in sickle cell disease in an oral presentation (abstract #271) at the 65th American Society of Hematology (ASH) Annual Meeting & Exposition, which is being hosted Dec. 9-12, 2023, in San Diego.

Key Points: 
  • The safety profile for mitapivat observed in the study was generally consistent with previously reported data in other studies of sickle cell disease and other hemolytic anemias.
  • Improvements were observed in annualized rates of sickle cell pain crises, and markers of hemolysis and erythropoiesis for both mitapivat treatment arms compared to placebo.
  • “Currently there are no approved oral therapies that address both sickle cell pain crises and chronic anemia, two of the hallmark symptoms of the disease.
  • Title: A Phase 2/3, Double-Blind, Randomized, Placebo-Controlled, Multicenter Study of Mitapivat in Patients With Sickle Cell Disease: RISE UP Phase 2 Results
    Oral Abstract Session: 114.

Mithra to receive EUR 2.5 million milestone payment from Fuji Pharma under ESTELLE® licensing agreement

Retrieved on: 
Monday, October 23, 2023

The submission marks another key milestone in the agreement for which Mithra will receive a EUR 2.5 million milestone payment.

Key Points: 
  • The submission marks another key milestone in the agreement for which Mithra will receive a EUR 2.5 million milestone payment.
  • Fuji Pharma obtained the right to commercialize both ESTELLE® and DONESTA® in Japan and the ASEAN region in 2016, targeting a potential market of 330 million patients.
  • David Horn Solomon, CEO at Mithra: “We are very proud of our partnership with Fuji Pharma and today’s announcement marks another key milestone in Mithra’s drive for growth and achieving its mission.
  • The global dysmenorrhea market was worth EUR 257 million in 20221.

South Africa's traditional medicines should be used in modern health care

Retrieved on: 
Tuesday, August 29, 2023

The growing recognition of traditional medicine resulted in the first World Health Organization global summit on the topic, in August 2023, with the theme “Health and Wellbeing for All”.

Key Points: 
  • The growing recognition of traditional medicine resulted in the first World Health Organization global summit on the topic, in August 2023, with the theme “Health and Wellbeing for All”.
  • Traditional medicines are widely used in South Africa, with up to 60% of South Africans estimated to be reliant on traditional medicine as a primary source of healthcare .
  • Recognition of traditional medicine as an alternative or joint source of healthcare to that of standard, conventional medicine has proven challenging.

What are traditional medicines?

    • Traditional medicine encompasses a number of healthcare practices aimed at either preventing or treating acute or chronic complaints through the application of indigenous knowledge, beliefs and approaches.
    • Traditional medicine practices also have a place in ritualistic activities and communicating with ancestors.
    • The harvested plants are most often sold at traditional medicine muthi markets.

Uses of medicinal plants

    • Read more:
      We tested plants used for contraception in South Africa.
    • Here's what we found

      The most commonly traded medicinal plants in South Africa are listed below along with their traditional uses: Buchu – Urinary tract infections; skin infections; sexually transmitted infections; fever; respiratory tract infections; high blood pressure; gastrointestinal complaints.

    • Read more:
      Africa is a treasure trove of medicinal plants: here are seven that are popular

      There are many ways in which traditional medicine may be used.

    • Harvesting of the roots, however, poses concerns about the conservation of these medicinal plants.
    • The South African government, with the draft policy on African traditional medicine Notice 906 of 2008 outlines considerations aimed at ensuring the conservation of these plants through counteracting unsustainable harvesting practises.

Obstacles to traditional medicine use

    • The limited research investigating interactions posed should a patient be making use of both traditional and conventional medicine is a concern.
    • During the COVID-19 pandemic, many patients used traditional remedies for the prevention of infection or treatment.

Sharing information


    The WHO in its Traditional Medicine Strategy for 2014-2023 report emphasised the need for using traditional medicine to achieve increased healthcare. Key role players from both systems of healthcare need to be able to share information freely. The need for policy development is key. Both conventional and traditional medicine practitioners would need to be aware of and engage with patients on all the medicines they are taking.

Understanding the whole patient

    • A comprehensive understanding of a patient’s health profile makes care easier.
    • This could also prevent treatment failures, promote patient safety, prevent adverse interactions and minimise risks.

Arjuna Natural's Turmeric-Frankincense Botanical Blend Relieves Menstrual Pain in Clinical Study

Retrieved on: 
Monday, July 31, 2023

KERALA, India, July 31, 2023 /PRNewswire/ -- A novel botanical formula powered by turmeric (Curcuma longa L), and frankincense (Boswellia serrata) has demonstrated abilities to alleviate menstrual cramps in a new clinical study. Rhuleave-K®, a breakthrough blend composed by the renowned nutraceutical company Arjuna Natural Pvt. Ltd., is poised to offer a natural holistic solution to   manage menstrual discomfort, allowing women to enjoy their daily activities without interruption.  

Key Points: 
  • The randomized, double-blinded, placebo-controlled study led by Dr. Divya Agarwal was published in the Journal of Clinical Medicine in June 2023.
  • Rhuleave-K® is a pioneering formula meticulously crafted by Arjuna Natural, as a botanical solution for providing pain relief.
  • This unique blend has already showcased potent analgesic activity in numerous clinical trials, specifically targeting musculoskeletal pain.
  • "Additional clinical trials are in the pipeline to further explore Rhuleave-K®'s potential role in providing fast action menstrual pain relief and synergistic all-round support" concludes Antony.

LEADING WOMEN'S WELLNESS BRAND O POSITIV ANNOUNCES THE LAUNCH OF FLO PMS COMPLETE

Retrieved on: 
Thursday, June 15, 2023

LOS ANGELES, June 15, 2023 /PRNewswire/ -- Today, O Positiv, the women's health brand behind FLO, the first-ever PMS support supplement on the market, introduces their newest product FLO PMS Complete. 

Key Points: 
  • LOS ANGELES, June 15, 2023 /PRNewswire/ -- Today, O Positiv , the women's health brand behind FLO , the first-ever PMS support supplement on the market, introduces their newest product FLO PMS Complete .
  • Since launching the FLO PMS Gummy in December 2018, O Positiv has positioned themselves as a premiere wellness brand with a range of products to address vaginal, digestive, skin, menstrual and menopausal health.
  • Each FLO PMS Complete tablet contains Acetaminophen, Caffeine and Pyrilamine Maleate to help alleviate menstrual and PMS related discomfort, such as cramps, aches, bloating, fatigue and water-related weight gain.
  • Now, with FLO Complete available, they can continue to use the trusted products of O Positiv for quick relief."

Myovant Sciences and Evidation Announce Survey Results of Unseen Burdens at Work and School of Individuals with Endometriosis and/or Uterine Fibroids

Retrieved on: 
Wednesday, May 17, 2023

Today, as part of National Women’s Health Week, Evidation and Myovant Sciences Ltd. (“Myovant”), a wholly owned subsidiary of Sumitovant Biopharma Ltd. (“Sumitovant”) announced results from a survey exploring the lived experiences of individuals with endometriosis and/or uterine fibroids.

Key Points: 
  • Today, as part of National Women’s Health Week, Evidation and Myovant Sciences Ltd. (“Myovant”), a wholly owned subsidiary of Sumitovant Biopharma Ltd. (“Sumitovant”) announced results from a survey exploring the lived experiences of individuals with endometriosis and/or uterine fibroids.
  • View the full release here: https://www.businesswire.com/news/home/20230517005194/en/
    “At Myovant, we know that stigma can often keep people quiet about periods, leading to delayed care and increased discomfort.
  • It also contributes to the lack of awareness about how conditions such as endometriosis and uterine fibroids can increase absenteeism and impact performance at work and school,” said Kalahn Taylor-Clark, vice president and head of Strategic Partnerships and Innovation at Myovant Sciences.
  • The survey covered four areas, including demographics, menstrual history and health, experiences at work or school, and experiences with medical providers.

Acetaminophen overdose is a leading cause of liver injury, but it is largely preventable

Retrieved on: 
Wednesday, April 26, 2023

“Larissa was healthy and within a week of the overdose, her liver failed, she received a liver transplant, and died from complications.

Key Points: 
  • “Larissa was healthy and within a week of the overdose, her liver failed, she received a liver transplant, and died from complications.
  • It was probably an attempt to treat her COVID-19 symptoms at a time when she was not eating well.
  • The three of us were developing educational tools on acetaminophen-related liver injury for health-care providers when we first learned of Larissa’s story.

Leading cause of acute liver injury

    • Yet, it is also a leading cause of acute liver injury, which can be fatal without a rescue liver transplant.
    • With millions around the world using acetaminophen every day, why are so few people aware of the dangers of overdose?
    • Approximately 4,500 Canadians are hospitalized from acetaminophen overdose each year — 12 hospitalizations per day.

Toxicity and overdose

    • In the first 24 hours after an overdose, there may only be mild symptoms such as nausea and vomiting, but many have no symptoms at all.
    • While the liver may heal itself, around six per cent of people hospitalized for acetaminophen overdose develop liver failure.
    • An antidote is available (an intravenous medicine called N-acetylcysteine) but it is most effective if given within 24 hours of overdose.

Using acetaminophen safely

    • Given that acetaminophen remains one of the most common medicines for treating pain and fever, people need to take steps to reduce their risk of liver injury.
    • Always check acetaminophen packages for the maximum single dose and 24-hour dose.
    • If the first acetaminophen dose is taken at noon, the 24-hour window ends at noon the next day.
    • When buying acetaminophen for common ailments like a headache or arthritis pain, reach for the regular strength product.